Strategic Growth Pillars: The leadership detailed a three-pillar roadmap: (1) A $1 million R&D investment to pioneer AI therapies addressing unmet needs; (2) A targeted $5–10 million biotech acquisition by July 2027 to broaden the pipeline; and (3) Uplisting to OTCQB by Q1 2026 and NASDAQ thereafter to boost liquidity and investor access. Unwavering Management Alignment: The team emphasized their $350,000 personal investment and salary deferral until reaching a $50 million valuation, aligning incentives wit ...

SEATTLE, July 28, 2025 (GLOBE NEWSWIRE) -- Fifty 1 Labs, Inc. (OTC: FITY), a leader in AI-powered health and wellness solutions, today announced it will host a virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST. The event will be broadcast on X (formerly Twitter), featuring Nobel Peace Prize recipient Dr. James Orbinski, who accepted the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières (Doctors Without Borders) for the organization's groundbreaking humanitarian medical ...

文章核心观点 - 公司旗下Fifty1 AI Labs完成REVIVE自适应平台试验，标志着在解决长新冠全球健康危机上的关键里程碑，有望实现5000万美元估值并引领320.6亿美元功能医学市场 [1] 分组1：试验成果与意义 - 试验是首个证明对长新冠有明确治疗益处的自适应平台试验，利用重新利用的药物解决该病症，符合公司通过人工智能驱动的药物再利用和功能医学革新医疗保健的愿景 [2] - 作为最大规模的长新冠试验，招募超600名参与者，实现同类研究最快招募，体现公司运营卓越和对科学卓越与运营效率的承诺 [3] 分组2：技术驱动 - 试验成功得益于Fifty1 AI Labs的专有贝叶斯和预测平台，该平台整合多种数据优化药物候选选择，加速有效治疗识别、缩短试验时间并降低成本 [4] 分组3：知识产权与商业机会 - 试验结果为基于多药治疗方案奠定基础，解锁知识产权开发机会，公司有望获得长新冠治疗市场大量份额，计划进行500 - 1000万美元的战略收购 [5] 分组4：战略规划 - 试验成功是公司实现5000万美元估值和引领功能医学市场的关键一步，公司将整合试验结果到研发战略，推进监管途径、建立研发中心并开展战略合作 [7] 分组5：公司简介 - 公司是内华达州的生物技术先驱，通过人工智能驱动的药物再利用和功能医学变革医疗保健，为预防保健和性能营养提供创新解决方案 [9]